Bracco subsidiary Blue Earth Diagnostics is directing attention to a number of presentations at the virtual annual meeting of the American Society for Radiation Oncology (ASTRO), which is being held October 23-28.
The company said that ASTRO talks will encompass the clinical use of its Axumin (fluciclovine F-18) PET radiopharmaceutical in recurrent prostate cancer, including a late-breaking abstract plenary session presentation by Emory University. In addition, information from an independent investigational study of fluciclovine F-18 PET in brain metastases will also be presented, Blue Earth said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
